Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
A look at the potential of microbiome-based therapies to transform medicine, and the progress of the closest such treatment to market. 30 July 2019
Biotechnology
Russian drugmaker Biocad is expanding into the therapeutic area of psoriatic drugs, through the launch of production of its new treatment Efleira (netakimab), according to recent statements by the company, reports The Pharma Letter’s local correspondent. 29 July 2019
Biotechnology
Shares in ProQR Therapeutics looked set to open around 6% up on Monday with news that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) status to a drug in development for Leber’s congenital amaurosis 10 (LCA10). 29 July 2019
Biotechnology
US biopharma major AbbVie today posted second-quarter 2019 financial results, showing that net revenue fell 0.3% to $8.26 billion, but still beat the average analyst estimate of $8.10 billion. 26 July 2019
Biotechnology
Positive top-line data for former Actelion candidate ponesimod will help further justify Johnson & Johnson’s30 billion outlay for the Swiss biotech. 26 July 2019
Biotechnology
US biotech firm Verastem Oncology saw its shares rise 22.14% to $1.60 in pre-market trading today, in reaction to a new licensing deal for its cancer drug. 26 July 2019
Biotechnology
British drugmaker AstraZeneca has won a positive reimbursement recommendation for its PARP blocker Lynparza (olaparib), through the Cancer Drugs Fund (CDF). 26 July 2019
Biotechnology
A white paper has claimed that RNA therapeutics will become a leading treatment modality within a decade. 25 July 2019
Biotechnology
Last year, Denmark-headquartered dermatology specialist LEO Pharma increased the size of its investment in R&D to 18%, compared to the 15% of the previous year. 25 July 2019
Biotechnology
In a day of mixed news for Bristol-Myers Squibb, the company revealed an upbeat second quarter results statement, fighting earlier pre-market declines on the back of a trial failure in lung cancer. 25 July 2019
Biotechnology
Maryland, USA-based gene therapy specialist Regenxbio has signed a deal with Swiss immunotherapy firm Neurimmune to develop novel AAV gene therapies. 25 July 2019
Biotechnology
In an R&D review presentation, Sage Therapeutics has announced it will pivot towards developing options for treatment-resistant depression. 25 July 2019
Biotechnology
A setback for Opdivo (nivolumab) was announced on Wednesday, as Bristol-Myers Squibb said a trial of the checkpoint inhibitor failed to meet its primary endpoint. 25 July 2019
Biotechnology
US biotech Celgene has agreed to pay $55 million to settle a class action lawsuit over alleged attempts by the drugmaker to block generic competition. 24 July 2019
Biotechnology
Acquisitive biotech Ligand Pharmaceuticals has bought fellow Californian firm Ab Initio Biotherapeutics for $12 million in cash. 24 July 2019
Biotechnology
Shares in Akebia Therapeutics finished the day around 6% up on Tuesday, after the firm announced the first ever filing for vadadustat, an investigational oral treatment for anemia due to chronic kidney disease (CKD). 24 July 2019
Biotechnology
In a major fillip for cancer biotech Jounce Therapeutics, Celgene has opted to license worldwide rights to JTX-8064, an antibody targeting the LILRB2 receptor on macrophages. 24 July 2019
Biotechnology
A set of quarterly financial results that exceeded expectations and led to improved full-year guidance prompted shares in Biogen increasing by 5% in Tuesday morning’s trading. 23 July 2019
Biotechnology
A company that calls itself the world-leading AI-driven drug discovery company has entered into a collaboration with Rallybio, a privately-held development-stage biotechnology company focused on rare diseases. 23 July 2019
Biotechnology
Germany’s Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the USA to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemophilia A treatment, Jivi, antihemophilic factor (recombinant) PEGylated-aucl 3000 IU. 23 July 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze